Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03975647
Recruitment Status : Recruiting
First Posted : June 5, 2019
Last Update Posted : March 2, 2021
Sponsor:
Information provided by (Responsible Party):
Seagen Inc.

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : April 30, 2024
Estimated Study Completion Date : April 30, 2024